Company search
Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Data as at: 10/03/2026
In
Objective
To seek capital appreciation through investment in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis.
AIC sector
Management group
Company website
Launch date
23/06/1997
March
Domicile
United Kingdom
Fund manager
Josh Golomb, Geoffrey C. Hsu
Dividend frequency
N/A
Wind-up provisions
An opportunity to vote on the continuation of the Company is given to shareholders every five years. The next such continuation vote will be held at the AGM to be held in 2030.
Continuation vote
5 yearly
| Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
|---|---|---|---|---|---|---|---|---|
| 261.04 | 284.34 | 1,285.00 | 1,389.40 | -7.51 | 9 | 0.00 | N/A | 1.1 (31/03/2025) |
Scroll
Dividends
Dividends declared in last 12 months
There have been no dividends in the last 12 months.
Performance (%)
| Return type | 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|---|
| Biotech Growth Trust | Share price total return | 62.5 | 49.4 | -9.8 | 122.3 |
| Biotechnology & Healthcare AIC sector | Share price total return | 20.2 | 7.9 | -16.0 | 99.6 |
Scroll
Share structure
Number of shares
20,314,314
Traded volumes (number of shares)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 39,202 | 1,375,542 | 24,115,446 | 105,410,288 |
| Average | N/A | 68,777 | 95,318 | 83,593 |
Scroll
Traded values (m)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 0.50 | 17.09 | 223.16 | 1,025.55 |
| Average | N/A | 0.85 | 0.88 | 0.81 |
Scroll
Trading details
| ISIN | Ticker | Traded currency | Stock exchange |
|---|---|---|---|
| GB0000385517 | BIOG | GBX | London Stock Exchange - MAIN Chi-x Europe Limited London Stock Exchange |
Scroll
Top holdings
Data as at : 30/11/2025
| Investment | % of total assets |
|---|---|
| Other Assets And Liabilities | 21.4 |
| UroGen Pharma Ltd | 4.0 |
| Trevi Therapeutics Inc | 3.3 |
| EyePoint Pharmaceuticals Inc | 3.1 |
| argenx SE | 3.1 |
| Cogent Biosciences Inc | 2.8 |
| Ascendis Pharma AS ADR | 2.8 |
| ORIC Pharmaceuticals Inc | 2.8 |
| Janux Therapeutics Inc Ordinary Shares | 2.8 |
| Krystal Biotech Inc | 2.7 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
